JP2024540461A5 - - Google Patents
Info
- Publication number
- JP2024540461A5 JP2024540461A5 JP2024529262A JP2024529262A JP2024540461A5 JP 2024540461 A5 JP2024540461 A5 JP 2024540461A5 JP 2024529262 A JP2024529262 A JP 2024529262A JP 2024529262 A JP2024529262 A JP 2024529262A JP 2024540461 A5 JP2024540461 A5 JP 2024540461A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence
- heavy chain
- light chain
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2021/131804 WO2023087255A1 (zh) | 2021-11-19 | 2021-11-19 | 双特异性抗体及其应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024540461A JP2024540461A (ja) | 2024-10-31 |
| JP2024540461A5 true JP2024540461A5 (enExample) | 2025-08-28 |
Family
ID=86395992
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024529262A Pending JP2024540461A (ja) | 2021-11-19 | 2021-11-19 | 二重特異性抗体及びその用途 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250002605A1 (enExample) |
| EP (1) | EP4435006A4 (enExample) |
| JP (1) | JP2024540461A (enExample) |
| KR (1) | KR20240100453A (enExample) |
| CN (3) | CN120818062A (enExample) |
| AU (1) | AU2021474386A1 (enExample) |
| CA (1) | CA3238406A1 (enExample) |
| MX (1) | MX2024006079A (enExample) |
| WO (1) | WO2023087255A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025190337A1 (zh) * | 2024-03-13 | 2025-09-18 | 武汉友芝友生物制药股份有限公司 | 使用抗EpCAM×CD3双特异性抗体改善或治疗恶性腹水的方法 |
| CN120346170A (zh) * | 2025-03-13 | 2025-07-22 | 武汉友芝友生物制药股份有限公司 | 抗EpCAM和CD3双特异性抗体药物组合物 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| RU2005137325A (ru) * | 2003-05-31 | 2006-09-10 | Микромет Аг (De) | Фармацевтическая композиция, содержащая конструкт, специфичный к ерсам |
| DK1629011T3 (da) * | 2003-05-31 | 2010-05-03 | Micromet Ag | Humane anti-humane-DC3-bindingsmolekyler |
| MXPA06004035A (es) * | 2003-10-16 | 2006-08-31 | Micromet Ag | Aglutinantes cd3 de-inmunizados multi-especificos. |
| EP2370467B1 (en) * | 2008-10-01 | 2016-09-07 | Amgen Research (Munich) GmbH | Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody |
| SG10201405434VA (en) * | 2009-09-18 | 2014-10-30 | Amgen Res Munich Gmbh | Dosage regimen for administering an epcamxcd3 bispecific antibody |
| PT3434767T (pt) * | 2010-11-30 | 2026-01-23 | Chugai Pharmaceutical Co Ltd | Agente terapêutico indutor de citotoxicidade |
| US9382329B2 (en) * | 2012-08-14 | 2016-07-05 | Ibc Pharmaceuticals, Inc. | Disease therapy by inducing immune response to Trop-2 expressing cells |
| EA035419B9 (ru) * | 2014-05-29 | 2020-08-07 | Мэкроудженикс, Инк. | Триспецифичные связывающие молекулы и способы их применения |
| CN104592392B (zh) * | 2015-01-21 | 2018-08-28 | 武汉友芝友生物制药有限公司 | 一种双特异性抗体EpCAM×CD3的构建及应用 |
| CN104592391B (zh) * | 2015-01-21 | 2020-08-21 | 武汉友芝友生物制药有限公司 | 一种双特异性抗体EpCAM×CD3的构建及应用 |
| WO2018028449A1 (en) * | 2016-08-08 | 2018-02-15 | Beigene, Ltd. | Method for predicting efficacy of immune checkpoint inhibitors in cancer patients |
| IL303187A (en) * | 2016-08-29 | 2023-07-01 | Akamis Bio Ltd | Adenovirus with bispecific T cell activator |
| WO2020168554A1 (zh) * | 2019-02-22 | 2020-08-27 | 武汉友芝友生物制药有限公司 | 改造的Fc片段，包含其的抗体及其应用 |
| US20220332757A1 (en) * | 2019-09-09 | 2022-10-20 | Wuhan Yzy Biopharma Co., Ltd. | Split intein and preparation method for recombinant polypeptide using the same |
-
2021
- 2021-11-19 MX MX2024006079A patent/MX2024006079A/es unknown
- 2021-11-19 CN CN202510748238.0A patent/CN120818062A/zh active Pending
- 2021-11-19 CA CA3238406A patent/CA3238406A1/en active Pending
- 2021-11-19 KR KR1020247020170A patent/KR20240100453A/ko active Pending
- 2021-11-19 EP EP21964409.3A patent/EP4435006A4/en active Pending
- 2021-11-19 WO PCT/CN2021/131804 patent/WO2023087255A1/zh not_active Ceased
- 2021-11-19 CN CN202510748232.3A patent/CN120818061A/zh active Pending
- 2021-11-19 JP JP2024529262A patent/JP2024540461A/ja active Pending
- 2021-11-19 US US18/711,094 patent/US20250002605A1/en active Pending
- 2021-11-19 CN CN202180104172.1A patent/CN118201960B/zh active Active
- 2021-11-19 AU AU2021474386A patent/AU2021474386A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7854016B2 (ja) | 腫瘍治療薬及びその応用 | |
| JP7099957B2 (ja) | ヒト化、マウスまたはキメラ抗ｃｄ４７モノクローナル抗体 | |
| CA2560305C (en) | Human anti-epidermal growth factor receptor antibody | |
| JP2022101693A5 (enExample) | ||
| JP7649744B2 (ja) | Ｂｔｎ３ａ結合タンパク質及びその使用 | |
| JP2020516240A5 (enExample) | ||
| JP2012525149A5 (enExample) | ||
| JP2018502050A5 (enExample) | ||
| AU2013355324A1 (en) | Blood-brain barrier (BBB) penetrating dual specific binding proteins | |
| CN105209493A (zh) | 用于诊断和治疗用途的her3特异性单克隆抗体 | |
| JP2023549537A5 (enExample) | ||
| TW201920282A (zh) | 抗egfr和pd-1的雙特異性抗體 | |
| JP2025038088A5 (enExample) | ||
| JP2021531255A5 (enExample) | ||
| JP2022546002A (ja) | ４価の対称型二重特異性抗体 | |
| JP2022521305A (ja) | 抗ｐｄ－ｌ１抗体及びその使用 | |
| TW202341984A (zh) | Ｈｅｒ３抗體藥物偶聯物及其用途 | |
| JP2024540461A5 (enExample) | ||
| JP2022512672A5 (enExample) | ||
| JP2021506817A5 (enExample) | ||
| JP2025517053A (ja) | 抗ｃＭｅｔ抗体、抗体薬物複合体、及びその調製方法と使用 | |
| JP2024542944A5 (enExample) | ||
| AU2021474386A1 (en) | Bispecific antibody and use thereof | |
| CN101233155B (zh) | 人抗表皮生长因子受体抗体 | |
| RU2024116487A (ru) | Биспецифическое антитело и его применение |